AbbVie/$ABBV
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About AbbVie
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
- Ticker
- $ABBV
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 57,000
- Headquarters
- North Chicago, United States
- Website
- www.abbvie.com
AbbVie Metrics
BasicAdvanced
$521B
50.77
$5.81
-
$6.83
2.35%
Price and volume
Market cap
$521B
52-week high
$298.74
52-week low
$190.75
Average daily volume
4.8M
Dividend rate
$6.83
Financial strength
Total debt to equity
-12.039
Interest coverage (TTM)
8.41%
Profitability
EBITDA (TTM)
32,409
Gross margin (TTM)
75.01%
Net profit margin (TTM)
15.67%
Operating margin (TTM)
37.53%
Effective tax rate (TTM)
19.24%
Revenue per employee (TTM)
$1,160,000
Management effectiveness
Valuation
Price to earnings (TTM)
50.773
Price to revenue (TTM)
7.902
Price to book
-87.8
Price to tangible book (TTM)
-5.75
Dividend yield (TTM)
2.32%
Forward dividend yield
2.35%
Growth
Revenue change (TTM)
10.68%
Earnings per share change (TTM)
339.80%
3-year revenue growth (CAGR)
6.18%
10-year revenue growth (CAGR)
10.09%
3-year earnings per share growth (CAGR)
16.71%
10-year earnings per share growth (CAGR)
4.61%
3-year dividend per share growth (CAGR)
-33.64%
10-year dividend per share growth (CAGR)
-2.72%
What the Analysts think about AbbVie
Analyst ratings (Buy, Hold, Sell) for AbbVie stock.
Analyst projections of the future price of AbbVie stock.
Bulls say / Bears say
AbbVie’s newer immunology drugs are growing fast: second-quarter Skyrizi and Rinvoq sales each rose about 24%, helping immunology revenue grow 15.1%. Management also raised its 2026 Skyrizi sales forecast to $21.7 billion. (AbbVie)
Neuroscience is becoming a second growth engine, with second-quarter revenue up 20.3% to $3.23 billion. Growth across products including Vraylar, Botox Therapeutic and newer migraine treatments helps broaden the business beyond immunology. (AbbVie)
AbbVie has promising oncology pipeline catalysts: its Phase 3 etentamig trial met both primary endpoints in multiple myeloma, and investigational Temab-A received two FDA Breakthrough Therapy Designations. These programmes could add future growth, although neither announcement guarantees approval. (AbbVie, AbbVie)
Humira is still shrinking sharply: second-quarter global sales fell 35.9% to $756 million as biosimilar competition continued. That decline remains a drag even as newer immunology drugs grow. (AbbVie)
AbbVie’s growth is increasingly reliant on Skyrizi and Rinvoq, but both are expected to face patent expiry within the next decade. The company will need to build further replacements before these key growth products lose exclusivity. (Yahoo Finance)
Unpredictable research and deal charges are making earnings harder to forecast: AbbVie’s October filing cut its 2026 adjusted EPS range by $0.11 after a $216 million acquired R&D and milestone charge. The company said it cannot forecast whether or when further such costs will arise. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 14 Oct 2026.
AbbVie Financial Performance
Revenues and expenses
AbbVie Earnings Performance
Company profitability
Upcoming events
AbbVie News
AllArticlesVideos
Funds containing AbbVie
AllUSDEURGBP
Fund name | Fund size | $ABBV weighting |
|---|---|---|
Invesco Health Care S&P US Select Sector$XLVS | $552M | 7.70% |
Invesco Health Care S&P US Select Sector£XLVP | $552M | 7.70% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 7.69% |
iShares MSCI World Health Care Sector Advanced€CBUF | $683M | 5.79% |
iShares MSCI World Health Care Sector Advanced£WHCA | $362M | 5.79% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.